Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.56 |
| ▸ | NPY4R | P50391 | 8/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY1R | P25929 | 8/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | CALCR | P30988 | 2/20 | 0.50 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31307264 | 0.85 | NTSR2 (0.56) | NPY2RNPY4RNPY5RNPY1REP300 | |
| SCHEMBL31307276 | 0.85 | NTSR1 (0.60) | NPY2RNPY4RNPY5RNPY1RNTSR2 | |
| SCHEMBL29811013 | 0.83 | F2 (0.57) | MAPK8MAPK9MAPK10F2NMUR2 | |
| SCHEMBL31182587 | 0.83 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30567736 | 0.82 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1REP300 | |
| SCHEMBL30978826 | 0.82 | NPY2R (0.57) | NPY2RNPY4RNPY5RNPY1RF2 | |
| SCHEMBL22263594 | 0.81 | NPY2R (0.67) | NPY2RNPY4RNPY5RNPY1REP300 | |
| SCHEMBL30578762 | 0.81 | NTSR2 (0.60) | NPY2RNPY4RNPY5RNPY1RMAPK8 | |
| SCHEMBL31738531 | 0.81 | NTSR1 (0.66) | NPY2RNPY4RNPY5RNPY1RNTSR2 | |
| SCHEMBL31548697 | 0.81 | NTSR1 (0.66) | NPY2RNPY4RNPY5RNPY1RNTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308135-B1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | ELIGO BIOSCIENCE (FR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250144006-A1 | COSMETIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | ELIGO BIOSCIENCE (FR) | 2025-05-08 | — | — | US | disclosed |
| US-20250122550-A1 | METHODS AND COMPOSITIONS FOR MAKING BACTERIOCINS AND ANTIMICROBIAL PEPTIDES | SYNGULON SA (BE) | 2025-04-17 | — | — | US | disclosed |
| US-12263192-B2 | Compositions for management of disorders of the gastrointestinal tract | PANTHERYX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12234299-B2 | Peptides for inducing bacteriocin synthesis and methods to identify and/or select and/or optimize the same | SYNGULON S.A. (BE) | 2025-02-25 | — | — | US | disclosed |
| US-12214070-B2 | Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins | ELIGO BIOSCIENCE (FR) | 2025-02-04 | — | — | US | disclosed |
| US-12195780-B2 | Methods and compositions for making bacteriocins and antimicrobial peptides | SYNGULON SA (BE) | 2025-01-14 | — | — | US | disclosed |
| US-11932672-B2 | Fermentation process | SYNGULON S.A. (BE) | 2024-03-19 | — | — | US | disclosed |
| WO-2024027860-A1 | A BACTERIOCIN COMPOSITION FOR CODING LINOCIN-M18-LIKE PROTEIN WITH ANTIMICROBIAL ACTIVITY AND ITS USAGE | Česká zemědělská univerzita v Praze (CZ) | 2024-02-08 | — | — | WO | disclosed |
| EP-4308135-A1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | Eligo Bioscience (FR) | 2024-01-24 | — | — | EP | disclosed |
| US-11541106-B2 | Method for killing bacteria with an engineered postbiotic | ELIGO BIOSCIENCE (FR) | 2023-01-03 | — | — | US | disclosed |
| US-11492651-B2 | Methods and compositions for making bacteriocins and antimicrobial peptides | SYNGULON SA (BE) | 2022-11-08 | — | — | US | disclosed |
| WO-2022195108-A2 | COSMETIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | ELIGO BIOSCIENCE (FR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022195115-A1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS FOR TREATING SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS | ELIGO BIOSCIENCE (FR) | 2022-09-22 | — | — | WO | disclosed |
| US-20220296499-A1 | COSMETIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | ELIGO BIOSCIENCE (FR) | 2022-09-22 | — | — | US | disclosed |
| WO-2022195112-A1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS FOR TREATING ACNEIFORM RASH | ELIGO BIOSCIENCE (FR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022195109-A1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | ELIGO BIOSCIENCE (FR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022195118-A1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS FOR TREATING CUTANEOUS LYMPHOMA | ELIGO BIOSCIENCE (FR) | 2022-09-22 | — | — | WO | disclosed |
| US-20220296686-A1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | ELIGO BIOSCIENCE (FR) | 2022-09-22 | — | — | US | disclosed |
| US-20220047646-A1 | COMPOSITIONS FOR MANAGEMENT OF DISORDERS OF THE GASTROINTESTINAL TRACT | PANTHERYX, INC. | 2022-02-17 | — | — | US | disclosed |